Development and preliminary testing of head and neck cancer related external lymphedema and fibrosis assessment criteria

European Journal of Oncology Nursing

Volumn 19, Issue 1, 2015, Pages 75-80

  Deng, Jie ^a   Ridner, Sheila H ^a   Wells, Nancy ^a   Dietrich, Mary S ^a   Murphy, Barbara A ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Assessment criteria; Fibrosis; Head and neck cancer; Instrument development; Lymphedema

Indexed keywords

AGED; COMPLICATION; FEMALE; FIBROSIS; HEAD AND NECK TUMOR; HUMAN; LYMPHEDEMA; MALE; MIDDLE AGED; PATHOLOGY; PILOT STUDY; QUESTIONNAIRE; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT;

AGED; FEMALE; FIBROSIS; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHEDEMA; MALE; MIDDLE AGED; PILOT PROJECTS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT;

EID: 84922935276     PISSN: 14623889     EISSN: 15322122     Source Type: Journal    
DOI: 10.1016/j.ejon.2014.07.006     Document Type: Article

References (24)

1. American Cancer Society Cancer facts & Figures2012 2012, (accessed 15.07.12.)http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf.
2. American Cancer Society, Donaldson S. Lymphedema: Understanding and Managing Lymphedema after Cancer Treatment 2006, American Cancer Society, Atlanta, GA.
3. Avraham T., Clavin N.W., Daluvoy S.V., Fernandez J., Soares M.A., Cordeiro A.P., et al. Fibrosis is a key inhibitor of lymphatic regeneration. Plastic and Reconstructive Surgery 2009, 124:438-450.
4. Avraham T., Zampell J.C., Yan A., Elhadad S., Weitman E.S., Rockson S.G., et al. Th2 differentiation is necessary for soft tissue fibrosis and lymphatic dysfunction resulting from lymphedema. Federation of American Societies for Experimental Biology Journal 2012, 27:1114-1126.
5. Bentzen S.M., Dorr W., Anscher M.S., Denham J.W., Hauer-Jensen M., Marks L.B., et al. Normal tissue effects: reporting and analysis. Seminars in Radiation Oncology 2003, 13:189-202.
6. Berger A.M. Oncology Nursing Society, ONS Foundation Endowment. Research Agenda 2009, (accessed 15.07.12.) http://www2.ons.org/media/ons/docs/research/research-agenda-2009-2013.pdf.
7. Dayyani F., Etzel C.J., Liu M., Ho C.H., Lippman S.M., Tsao A.S. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head and Neck Oncology 2010, 2:1-11.
8. Deng J., Murphy B.A., Dietrich M.S., Wells N., Wallston K.A., Sinard R.J., et al. Impact of secondary lymphedema after HNC treatment on symptoms, functional status, and quality of life. Head and Neck 2013, 35:1026-1035.
9. Deng J., Ridner S.H., Dietrich M.S., Wells N., Murphy B.A. Assessment of external lymphedema in patients with HNC: a comparison of four scales. Oncology Nursing Forum 2013, 40:501-506.
10. Deng J., Ridner S.H., Dietrich M.S., Wells N., Wallston K.A., Sinard R.J., et al. Prevalence of secondary lymphedema in patients with head and neck cancer. Journal of Pain and Symptom Management 2012, 43:244-252.
11. Deng J., Ridner S.H., Murphy B.A. Lymphedema in patients with head and neck cancer. Oncology Nursing Forum 2011, 38:E1-E10.
12. Dennert G., Horneber M. Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients. Cochrane Database of Systematic Reviews 2006, 3:CD005037.
13. DeVellis R.F. Scale Development: Theory and Applications 2003, Sage Publications, Inc., Thousand Oaks, Calif. second ed.
14. Fakhry C., Westra W.H., Li S., Cmelak A., Ridge J.A., Pinto H., et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. Journal of the National Cancer Institute 2008, 100:261-269.
15. Földi M.D., Földi E., Strössenreuther R.H.K., Kubik S. Földi's Textbook of Lymphology: for Physicians and Lymphedema Therapists 2007, Elsevier, Urban & Fischer Verlag, Muchen, Germany. second ed.
16. Hanna G.J., Haddad R.I., Lorch J.H. Induction chemotherapy for locoregionally advanced head and neck cancer: past, present, future?. The Oncologist 2013, 18:288-293.
17. Lymphoedema Framework Best Practice of the Management of Lymphoedema. International Consensus 2006, MEP Ltd, London.
18. Murphy B.A., Gilbert J., Ridner S.H. Systemic and global toxicities of head and neck treatment. Expert Review of Anticancer Therapy 2007, 7:1043-1053.
19. Oral Cancer Foundation HPV Connection, the Human Papilloma Virus 2012, (accessed 15.07.12.)http://oralcancerfoundation.org/hpv/index.htm.
20. Posner M.R. Integrating systemic agents into multimodality treatment of locally advanced head and neck cancer. Annals of Oncology 2010, 21:vii246-vii251.
21. Ridner S.H. Lymphedema of the head and neck: an overview. National Lymphedema Network Link 2008, 20:1-3.
22. Smith B.G., Lewin J.S. Lymphedema management in head and neck cancer. Current Opinion in Otolaryngology & Head and Neck Surgery 2010, 18:153-158.
23. United States Department of Health and Human Services, National Institutes of Health, National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 (CTCAE) 2006, (accessed 05.07.12.)http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
24. United States Department of Health and Human Services, National Institutes of Health, National Cancer Institute Head and Neck Cancers 2012, (accessed 15.07.12.). http://www.cancer.gov/cancertopics/types/head-and-neck.